 Management of children with newly diagnosed immune thrombocytopenia ( ITP<ORGANIZATION> ) consists of careful observation or immunomodulatory treatment. Observational studies suggest a lower risk of chronic ITP in children after intravenous immunoglobulin ( IVIg<ORGANIZATION> ) treatment. In this multicenter randomized trial, children aged 3 months-16 years with newly diagnosed ITP<ORGANIZATION>, platelet counts ≤20 × 10